FDA’s new Acting Commissioner of Food and Drugs, Norman Sharpless, promised last week that he will pick up where outgoing Commissioner Scott Gottlieb left off in strengthening nutrition policy and regulation to improve the public’s health and implementing...
Fundamental questions of identity and intended use will have to be answered before CBD can take center stage as a legal dietary ingredient. The upcoming meeting with FDA will likely provide a start, but hopes that all issues will be quickly solved seem...
The US Court of Appeals for the Federal Circuit backed the ITC’s refusal to not investigate Amarin Pharma’s complaint alleging that certain doses of omega-3s should not be imported as dietary supplements.
What’s the typical profile of an energy drink consumer in the US, and how much are they drinking? Researchers from the Harvard T.H. Chan School of Public Health analyzed data from a national health survey to get some answers.
The Center for Science in the Public Interest (CSPI) sent a letter to the FDA yesterday, asking the agency to take enforcement action against 15 companies selling products as dietary supplements to help smokers quit.
The recent slew of warning letters on DMHA and phenibut signals a new scrutiny on the part of FDA of ingredient status without reference to other issues, says an attorney with a long history in the field.
The nootropic category is again under that microscope as the Federal Trade Commission has announced the settlement of a case over unsupported cognitive support claims that generated a combined $26 million in fines.
By Michael McGuffin, president, American Herbal Products Association
Looking back 25 years, there are several remarkable aspects of the Dietary Supplement Health and Education Act (DSHEA) amendments to the Food Drug and Cosmetic Act (FD&C Act), which transformed how dietary supplements are regulated.